Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 4Neoplasm Metastasis 3Rectal Neoplasms 2Leukemia, Myeloid, Acute 2Carcinoma, Non-Small-Cell Lung 2Uveal Melanoma 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Sarcoma 1Recurrence 1Prostatic Neoplasms 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Ovarian Neoplasms 1Neurofibrosarcoma 1Neoplasms 1Myeloproliferative Disorders 1Multiple Myeloma 1Lung Neoplasms 1Lung Cancer - Malignant Pleural Mesothelioma 1Liver Neoplasms 1Leukemia 1Hematologic Neoplasms 1Gastrointestinal Stromal Tumors 1Fallopian Tube Neoplasms 1Esophagogastric Cancer 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms, Male 1Blast Crisis 1

Interventions

zirconium-89-trastuzumab 1STA 9090 1Positron-Emission Tomography 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Esophagogastric Cancer × STA 9090 × Clear all
NCT01167114 2023-11-02

STA-9090 in Previously Treated Patients With Advanced Esophagogastric Cancer

Massachusetts General Hospital

Phase 2 Completed
28 enrolled
Gastrointestinal

Esophagogastric Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡